CRMD - NASDAQ

CorMedix Inc.

CRMD·NASDAQ

$8.23

+0.73%

HealthcareBiotechnology

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$645.66M

EPS2.2500

P/E Ratio3.66

Earnings Date08/06/2026

826.14M

Assets

595%

3Y+1232.0%

5Y+1575.0%

10Y+3671.0%

420.83M

Total Liabilities

1131%

3Y+5930.0%

5Y+8176.0%

10Y+10185.0%

405.31M

Total Equity

379%

3Y+636.0%

5Y+817.0%

10Y+2175.0%

CorMedix Inc. Funding & Solvency Profile

CRMD · NASDAQ

Current Assets

Cash & Cash Equivalents145.82M

Net Receivables171.23M

Inventory29.72M

Other Current Assets0.00

Total Current Assets350 M

Non-Current Assets

Property, Plant & Equipment9.93M

Goodwill & Intangible Assets409.07M

Long-Term Investments0.00

Other Non-Current Assets-9.93M

Total Non-Current Assets0

Total Assets

826.14M

Financial Health Analysis

Current Ratio

2.01x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

1.04x

Elevated leverage. Debt exceeds equity, which amplifies both gains and risks. Monitor debt servicing ability.

Working Capital

176 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

42% Current

Balanced asset mix between current and non-current assets, typical of many stable businesses.

CorMedix Inc. Balance Sheet

CRMD • NASDAQ

CorMedix Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018	Dec 2017	Dec 2016	Dec 2015	Dec 2014	Dec 2013	Dec 2012	Dec 2011	Dec 2010	Dec 2009	Dec 2008
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	145.8M	40.7M	43.6M	43.4M	53.3M	41.9M	16.5M	17.6M	10.4M	8.1M	11.8M	4.3M	2.4M	835.5K	2M	8.3M	1.5M	1.4M
Short-Term Investments	3.7M	11M	32.4M	15.6M	12.1M	4.4M	12M	0.0	1.6M	12.1M	23.6M	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash & Short-Term Investments	149.5M	51.7M	76M	59M	65.5M	46.3M	28.5M	17.6M	12M	20.2M	35.4M	4.3M	2.4M	835.5K	2M	8.3M	1.5M	1.4M
Net Receivables	171.2M	51.7M	0.0	0.0	45.4K	3.4K	0.0	10.9K	64.1K	12K	315.8K	80.2K	2.3K	0.0	493.9K	0.0	0.0	0.0
Accounts Receivables	171.2M	51.7M	0.0	0.0	45.4K	3.4K	0.0	10.9K	64.1K	12K	315.8K	80.2K	2.3K	0.0	493.9K	280.9K	0.0	0.0
Inventory	29.7M	7.6M	2.1M	0.0	3K	143.6K	338.5K	428.5K	594.2K	166.7K	376.6K	463K	80K	0.0	0.0	0.0	0.0	0.0
Prepaids	0.0	152.8K	353.6K	623.7K	52K	1.4M	446.4K	422.2K	367.2K	372.1K	379K	155.2K	233K	11.2K	51.8K	205.4K	178.1K	0.0
Other Current Assets	0.0	3.5M	959.7K	-91.3K	902.1K	273.5K	54.8K	179.7K	258.2K	1.1M	601.7K	0.0	226.8K	0.0	0.0	0.0	0.0	4.7K
Total Current Assets	350.5M	114.6M	79.5M	59.6M	66.5M	48.2M	29.3M	18.7M	13.3M	21.8M	37.1M	5M	2.9M	1.1M	2.5M	8.8M	1.7M	1.4M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	9.9M	2.3M	2.5M	2.4M	2.4M	1.1M	126.8K	160.9K	186.3K	69.7K	37.9K	41.5K	36.1K	4.7K	11.7K	22.3K	24.1K	34.1K
Goodwill	30M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Intangible Assets	379.1M	1.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Goodwill & Intangible Assets	409.1M	1.8M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Long-Term Investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	13.3K	11.7K	0.0
Tax Assets	16.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other Non-Current Assets	-9.9M	105.4K	103.1K	102.3K	102.3K	0.0	0.0	0.0	0.0	5K	5K	18.3K	15.7K	13.3K	13.3K	0.0	506.5K	201.6K
Total Non-Current Assets	425.4M	4.3M	2.6M	2.5M	2.5M	1.1M	126.8K	160.9K	186.3K	74.7K	42.9K	59.8K	51.8K	18K	25K	35.7K	542.4K	235.6K
Other Assets	50.3M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Assets	826.1M	118.8M	82.1M	62M	68.9M	49.3M	29.5M	18.8M	13.5M	21.9M	37.1M	5.1M	3M	1.2M	2.6M	8.8M	2.2M	1.6M
LIABILITIES
CURRENT LIABILITIES
Total Payables	20.6M	3.7M	4.3M	2.2M	2.2M	1.1M	1M	2.6M	1.8M	1.6M	1.8M	893.4K	939.8K	928.6K	913.5K	1.1M	549.6K	822.1K
Accounts Payable	7.9M	1.7M	4.3M	2.2M	2.2M	1.1M	1M	2.6M	1.8M	1.6M	1.7M	893.4K	939.8K	928.6K	913.5K	1.1M	549.6K	822.1K
Other Payables	12.8M	2M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	67.2K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Accrued Expenses	0.0	30M	7M	4M	3M	2.9M	1.3M	1.1M	755.2K	2.3M	1.2M	13.4K	198K	278.2K	296.5K	436.4K	2.6M	0.0
Short Term Debt	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	269.7K	0.0	0.0	13.8M	11.7M
Capital Lease Obligations (Current)	1.4M	167.9K	150.6K	134.8K	121.4K	109.1K	2K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Tax Payables	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	1.8K	67.2K	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue	0.0	0.0	0.0	0.0	0.0	0.0	2.2K	11K	88.4K	104.2K	130.4K	8.8K	0.0	0.0	0.0	0.0	0.0	0.0
Other Current Liabilities	152.2M	0.0	0.0	0.0	0.0	0.0	3.5M	4.1M	3.6M	0.0	0.0	508.1K	536.3K	140K	95K	0.0	0.0	1.2M
Total Current Liabilities	174.3M	33.8M	11.4M	6.3M	5.3M	4.2M	5.8M	7.8M	6.3M	4.1M	3.1M	1.4M	1.7M	1.6M	1.3M	1.6M	16.9M	13.6M
NON-CURRENT LIABILITIES
Long Term Debt	144.6M	0.0	0.0	0.0	0.0	0.0	0.0	6.1M	0.0	0.0	0.0	0.0	0.0	16.1K	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	28.9K	37.5K	0.0	0.0	0.0	16.8K	0.0	0.0
Other Non-Current Liabilities	99.1M	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	403.0	5.3M	-3.9K	14.5K	0.0	0.0	0.0
Total Non-Current Liabilities	246.6M	349.1K	517K	667.6K	802.4K	923.7K	2.7K	6.1M	0.0	0.0	28.9K	37.9K	5.3M	12.2K	14.5K	16.8K	0.0	0.0
Capital Lease Obligations	4.3M	517K	667.6K	802.4K	923.8K	1M	2.7K	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Total Liabilities	420.8M	34.2M	11.9M	7M	6.1M	5.1M	5.8M	13.9M	6.3M	4.1M	3.1M	1.5M	7M	1.6M	1.3M	1.6M	16.9M	13.6M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	137.0	182.0	182.0	182.0	242.0	242.0	420.0	420.0	450.0	450.0	950.0	857.0	0.0	0.0	0.0	0.0	0.0
Common Stock	79K	64.4K	54.9K	42.8K	38.1K	33.6K	25.7K	108.9K	71.4K	40.4K	36K	22.5K	16.6K	11.4K	11.4K	11.4K	981.0	1.8K
Additional Paid-In Capital	581.8M	424.1M	391.7M	330.3M	308.3M	261.5M	218.9M	183.7M	159.2M	136.9M	128.3M	79.7M	51.7M	45.9M	44.2M	43.5M	10.6M	5.2M
Retained Earnings	-176.6M	-339.6M	-321.7M	-275.4M	-245.7M	-217.4M	-195.4M	-179M	-152.2M	-119.2M	-94.4M	-76.2M	-55.8M	-46.4M	-42.9M	-36.2M	-25.3M	-17.2M
Accumulated Other Comprehensive Income/Loss	3K	90.6K	94.1K	82.7K	87.1K	102K	97.3K	96.5K	98.4K	81.2K	62.1K	99K	-9.3K	-57K	0.0	-37.8K	-25.6K	-1.1K
Other Total Stockholders' Equity	0.0	0.0	0.0	0.0	0.0	1.0	0.0	0.0	0.0	0.0	0.0	-110.0	-146.0	-146.0	-146.0	0.0	25.6K	0.0
Total Stockholders' Equity	405.3M	84.7M	70.1M	55.1M	62.8M	44.2M	-195.4M	-179M	-152.2M	17.8M	34M	3.6M	-4M	-475.4K	1.2M	7.3M	-14.7M	-12M
Total Equity	405.3M	84.7M	70.1M	55.1M	62.8M	44.2M	-195.4M	-179M	-152.2M	17.8M	34M	3.6M	-4M	-475.4K	1.2M	7.3M	-14.7M	-12M
SUMMARY
Total Liabilities & Equity	826.1M	118.8M	82.1M	62M	68.9M	49.3M	-189.6M	-165.1M	-145.9M	21.9M	37.1M	5.1M	3M	1.2M	2.6M	8.8M	2.2M	1.6M
Total Investments	3.7M	11M	32.4M	15.6M	12.1M	4.4M	12M	0.0	1.6M	12.1M	23.6M	0.0	0.0	0.0	0.0	13.3K	11.7K	0.0
Total Debt	148.9M	517K	667.6K	802.4K	923.8K	1M	4.7K	6.1M	0.0	0.0	0.0	0.0	0.0	269.7K	0.0	0.0	13.8M	11.7M
Net Debt	3.1M	-40.1M	-43M	-42.6M	-52.4M	-40.9M	-16.5M	-11.5M	-10.4M	-8.1M	-11.8M	-4.3M	-2.4M	-565.7K	-2M	-8.3M	12.3M	10.3M
Shares Outstanding	74,642,586	74,642,586	74,642,586	74,642,586	74,642,586	74,642,586	74,642,586	74,642,586	74,642,586	74,642,586	74,642,586	74,642,586	74,642,586	74,642,586	74,642,586	74,642,586	74,642,586	74,642,586

SEC Filings

CRMD - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 14, 2026	May 14, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 14, 2026	March 31, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 29, 2026	June 23, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 27, 2026	April 27, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 06, 2026	March 06, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 05, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	March 05, 2026	March 05, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 08, 2026	January 05, 2026	2026	View Filing
8-K 8-K 2025 N/A	November 12, 2025	November 12, 2025	2025	View Filing
10-Q 10-Q 2025 Q3 Q3	November 12, 2025	September 30, 2025	2025	View Filing

Showing 1 to 10 of 409 filings

Related Guides

Blog Categories

Continue your CRMD research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.